Category: Pharmaceuticals
-
Bionxt Solutions (BNXT.C): Seeking to confirm national-level cancer drug patent
As the world increasingly faces the complexities of autoimmune and neurodegenerative diseases, new medical advancements are crucial to better serve patients’ needs. Enter Bionxt Solutions Inc. (BNXT.C), a bioscience innovator making moves with its groundbreaking sublingual (under-the-tongue) drug delivery technology. This technology, now in the process of securing national-level patents globally, represents a shift from…
-
BioNxt Solutions (BNXT.C) to spark marketing as ODF human studies begin
Biotech companies are notoriously difficult to find investor love for in Canada, at least historically, so it’s no surprise that BioNxt Solutions (BNXT.C) is headquartered in Germany. That proximity to German investors is likely to come in handy as the company seeks to start cranking out marketing coverage after several months of prepping their Oral…
-
Alpha Cognition Inc (ACOG.C) has navigated the Alzheimers FDA process like a champ
People really don’t like pharma companies in Canada. We’ve had some monster megacorporations come out of Canada in the pharma space, and the biotech space, and a lot of them turned out to be robber baron villains with twirly moustaches looking to monetize mom’s ailments in ways that ensure the highest possible return in the…
-
Explaining biotech: Bionxt Solutions (BNXT.C) advances MS product through animal study
Bionxt Solutions Inc. (BNXT.C) has finished a study on a new type of medicine strip that dissolves in your mouth. This strip is designed to treat multiple sclerosis (MS), a condition that affects the brain and nerves. The study looked at how well and how quickly the body absorbs the medicine from this strip compared…
-
Lophos Pharma (MESC.C) now readies for natural and synthetic peyote production
Lophos Pharmaceuticals Corp. (MESC.C), a key player in the Canadian biosciences/psychedelics sector, has made a significant leap forward in the field of psychoactive compound research and development as it has announced the successful finalization of a new synthetic mescaline production protocol, marking a major milestone in the accessibility and study of psychoactive substances. This development…
-
Revive Therapeutics (RVV.C) takes on long covid with new phase 2/3 FDA protocol
Allow me to back into the lede a bit here. THE STORY OF ROCKERFELLER VS THE WORMS In the early part of the 20th century, the American South was known colloquially as ‘the hookworm belt.’ Hookworms are parasites that like a human host. They corkscrew into your feet when you walk by them barefoot, travel…
-
Optimi Health (OPTI.C) transforming psychedelic treatment and wellness
In Canada, the prevalence of depression and mental health disorders has shown a worrying increase. According to data from 2022, over 5 million Canadians, accounting for 18% of the population aged 15 and older. This growing trend underscores the importance of addressing mental health issues at a societal and policy level, with an emphasis on…
-
InnoCan Pharma’s (CSE: INNO) investment potential in the Pharmaceuticals Sector: A Balanced View
InnoCan Pharma Corporation, trading on the Canadian Securities Exchange under the symbol INNO, FSE: IP4, and OTC: INNPF, is a pharmaceutical technology company that has garnered attention in the investment community. This article evaluates its potential as an investment option in the pharmaceuticals space, considering both its recent achievements and challenges. Business Model and Strategic…
-
Bionxt Solutions (BNXT.C) shows how pivots don’t have to mean resets
Several years back, Hugh Rogers was in my office talking about his cannabis company. Way back then, the plan was to grow in Germany and be first on the continent, using an old wartime bunker as a ‘safe growing facility’. Those plans morphed quickly as the reality of the cannabis space became clear. The cannabis…